Electronic Supplementary Material (ESI) for Green Chemistry. This journal is © The Royal Society of Chemistry 2018

> Electronic Supplementary Material (ESI) for Green Chemistry. This journal is © The Royal Society of Chemistry 2014

Green Chemistry

Solid acid-catalyzed domino cyclization reaction: regio- and diastereoselective synthesis of pyrido[2,3-*d*]pyrimidine derivatives bearing three contiguous stereocenters

Furen Zhang,* Chunmei Li and Xuezheng Liang

School of Chemistry and Chemical Engineering, Zhejiang Key Laboratory of Alternative Technologies for Fine Chemicals Process, Shaoxing University, Shaoxing, Zhejiang Province 312000, China

Electronic Supplementary Information (ESI)

Supplementary Information Available: complete product characterization data, analytical details.

Table of Contents

1. General information.	S2
2. X-ray Crystallography	S2
3. Synthesis and property of solid acid (C-SO ₃ H) catalyst	S3
4. General procedure for the synthesis of 4	S3
5. General procedure for the synthesis of 6	S3
6. Spectral data of the compounds	S4
7. ¹ H and ¹³ C NMR Spectra	S16

General information

All the reagents were commercially available and used without further purification, unless otherwise stated. IR spectra were determined on an FT-IR-Tensor 27 spectrometer. ¹HNMR spectra were recorded on a 400 MHz instrument (Bruker Avance 400 Spectrometer). Chemical shifts (δ) are given in ppm relative to TMS as the internal reference, with coupling constants (*J*) in Hz. ¹³C NMR spectra were recorded at 100 MHz. Chemical shift were reported in ppm with the internal chloroform signal at 77.0 ppm or dimethyl sulphoxide signal at 39.9 ppm as a standard. HRMS (ESI) was measured with a Bruker Daltonics APEXII instrument. Single-crystal X-ray diffraction measurement was carried out on a Rigaku Saturn CCD diffractometer at 100(2) K using graphite monochromated Mo K α radiation ($\lambda = 0.71073$ Å). The structure was solved by direct methods and refined by full-matrix least squares on F^2 using the SHELXTL-97 program package. According to literature method,¹ the carbonaceous material catalyst was prepared using furaldehyde and hydroxyethylsulfonic acid as substrates.

X-ray Crystallography

Single-crystal X-ray diffraction measurement was carried out on a Rigaku Saturn CCD diffractometer at 100(2) K using graphite monochromated Mo K α radiation ($\lambda = 0.71073$

Å). An empirical absorption correction was applied using the SADABS program. The structure was solved by direct methods and refined by full-matrix least squares on F^2 using the SHELXTL-97 program package.

Synthesis and property of solid acid (C-SO₃H) catalyst

According to literature method,¹ furaldehyde (10 g), hydroxyethylsulfonic acid (5 g) were dropped into deionized water (80 mL) and placed in 100 mL Teflon-lined stainless steel autoclaves, which were heated in an oven at 200 °C for 4 h. The resulting products were filtered, washed with water and methanol, and dried in a vacuum oven at 110 °C for 5 h. The acidity of the solid acid was 2.4 mmol/g, which was determined through the neutralization titration. This solid acid owned much higher acidity than that of the sulfonated solid acid, which was obtained via the sulfonation of the inactive carbon. The acid strength of the catalyst was determined by thermodesorption of chemisorbed ammonia (NH₃-TPD). The result showed that the catalyst had great acid strength in which ammonia was desorbed at 400 to 600 °C. IR (KBr) = 3020 (Ar-H), 1704 (C=O), 1604 (C=C), 1204 (C-O), 1040 (S=O), 940 (S-O) cm⁻¹.

General procedure for the synthesis of 4

In a 10-mL reaction vial, 2,6-diaminopyrimidin-4(3*H*)-one (0.5 mmol), nitroolefin (0.5 mmol), aldehyde (0.5 mmol), carbonaceous material (C-SO₃H) (10 mg) as well as water (3.0 mL), were added respectively and then capped. The mixture was stirred until TLC revealed that conversion of the substrates was complete, then, the reaction mixture was cooled to room temperature. The resulted precipitate was filtered and dried along with the catalyst. The crude product was further purified by recrystallization from hot ethanol/N,N-dimethylformamide to give the pure desired product.

General procedure for the synthesis of 6

In a 10-mL reaction vial, 6-aminopyrimidine-2,4(1*H*,3*H*)-dione **5a** or 6-amino-2-thioxo-2,3-dihydropyrimidin-4(1*H*)-one **5b** (0.5 mmol), (*E*)-1-methyl-4-(2-nitrovinyl)benzene (0.5 mmol), 4-methylbenzaldehyde (0.5 mmol), carbonaceous material (C-SO₃H) (10 mg) as well as water (3.0 mL), were added respectively and then capped. The mixture

was stirred until TLC revealed that conversion of the substrates was complete, then, the reaction mixture was cooled to room temperature. The resulted precipitate was filtered and dried along with the catalyst. The crude product was further purified by recrystallization from hot ethanol/*N*,*N*-dimethylformamide to give the pure desired product.

Spectral data of the compounds



2-amino-6-nitro-5-phenyl-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4(3*H*)one (4a)

Yellow powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.09 (br, s, 1H, NH), 7.34-7.38 (m, 2H, ArH), 7.25-7.29 (m, 3H, ArH), 7.17 (s, 1H, NH), 7.11 (d, J = 8.4 Hz, 2H, ArH), 7.04 (d, J = 8.0 Hz, 2H, ArH), 6.21 (br, s, 2H, NH₂), 4.92 (t, J = 2.6 Hz, 1H, CH), 4.50 (d, J = 3.2 Hz, 1H, CH), 4.39 (d, J = 2.0 Hz, 1H, CH), 2.27 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.8, 160.0, 154.4, 143.0, 138.0, 134.3, 130.2, 129.4, 129.0, 128.6, 127.8, 127.4, 127.1, 89.4, 83.0, 52.7, 21.1; IR (KBr, v, cm⁻¹): 3499, 3393, 3064, 2901, 1642, 1594, 1545, 1474, 1385, 1322, 1285, 1075, 1030, 770, 621; HRMS (ESI) m/z calcd for C₂₀H₁₉N₅O₃ [M + H]⁺: 378.1561, found: 378.1565.



2-amino-5-(4-fluorophenyl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4b)

Purple powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.11 (br, s, 1H, NH), 7.29-7.33 (m, 2H, ArH), 7.17-7.20 (m, 3H, ArH+NH), 7.12 (d, J = 8.0 Hz, 2H, ArH), 7.04 (d, J = 8.0 Hz, 2H, ArH), 6.23 (br, s, 2H, NH₂), 4.92 (t, J = 2.8 Hz, 1H, CH),

4.51 (d, J = 3.6 Hz, 1H, CH), 4.39 (d, J = 2.0 Hz, 1H, CH), 2.27 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.1 ($J_{CF}^1 = 143.0$ Hz), 159.9, 154.4, 139.1 ($J_{CF}^4 = 2.8$ Hz), 139.0, 137.9, 134.3, 130.5 ($J_{CF}^3 = 8.0$ Hz), 129.3, 127.1, 115.6 ($J_{CF}^2 = 22.0$ Hz), 89.3, 83.1, 52.7, 21.1; IR (KBr, v, cm⁻¹): 3418, 2921, 1648, 1609, 1545, 1471, 1329, 1215, 1074, 1011, 866, 617; HRMS (ESI) calcd for C₂₀H₁₈FN₅O₃ (M + H)⁺: 396.1466, found: 396.1476.



2-amino-5-(4-chlorophenyl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4c)

Green powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.11 (br, s, 1H, NH), 7.39 (d, J = 8.4 Hz, 2H, ArH), 7.30 (d, J = 8.0 Hz, 2H, ArH), 7.22 (s, 1H, NH), 7.12 (d, J = 8.0 Hz, 2H, ArH), 7.05 (d, J = 8.4 Hz, 2H, ArH), 6.23 (br, s, 2H, NH₂), 4.94 (t, J = 2.8 Hz, 1H, CH), 4.53 (d, J = 3.6 Hz, 1H, CH), 4.38 (d, J = 2.0 Hz, 1H, CH), 2.27 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.7, 160.0, 154.4, 142.0, 138.0, 134.3, 131.9, 130.6, 129.3, 128.8, 127.2, 89.1, 82.9, 52.8, 21.1; IR (KBr, v, cm⁻¹): 3419, 2921, 1649, 1610, 1546, 1472, 1370, 1325, 1215, 1074, 846, 676; HRMS (ESI) calcd for C₂₀H₁₈ClN₅O₃ (M + H)⁺: 412.1171, found: 412.1173.



2-amino-5-(4-bromophenyl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4d)

White powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.01 (br, s, 1H, NH), 7.49 (d, J = 8.4 Hz, 2H, ArH), 7.09-7.15 (m, 4H, ArH),7.01 (d, J = 7.6 Hz, 2H, ArH), 5.43 (br, s, 1H, NH), 5.24 (br, s, 2H, NH₂), 4.80 (s, 1H, CH), 4.45 (s, 2H, CH), 2.30 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 163.0, 159.9, 154.2, 139.2, 138.3, 137.8, 132.5, 129.9, 129.8, 127.9, 126.3, 88.9, 83.7, 52.7, 40.8, 21.1; IR (KBr, v, cm⁻¹): 3420, 2920, 1647, 1607, 1544, 1471, 1372, 1326, 1075, 1011, 845, 677; HRMS (ESI) calcd for $C_{20}H_{18}BrN_5O_3$ (M + H)⁺: 456.0666, found: 456.0661.



2-amino-6-nitro-5-(4-nitrophenyl)-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4e)

Brown powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.21 (br, s, 1H, NH), 8.16 (d, J = 8.4 Hz, 2H, ArH), 7.54 (d, J = 8.4 Hz, 2H, ArH), 7.28 (s, 1H, NH), 7.10 (d, J = 8.0 Hz, 2H, ArH), 7.01 (d, J = 8.0 Hz, 2H, ArH), 6.31 (br, s, 2H, NH₂), 5.02 (t, J = 2.4 Hz, 1H, CH), 4.58 (d, J = 2.4 Hz, 1H, CH), 4.48 (d, J = 2.4 Hz, 1H, CH), 2.23 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.9, 160.1, 154.5, 150.5, 146.9, 138.2, 134.1, 130.1, 129.4, 127.1, 124.0, 88.5, 82.7, 53.2, 21.1; IR (KBr, v, cm⁻¹): 3422, 2922, 1649, 1608, 1544, 1375, 1323, 1286, 1077, 845, 723; HRMS (ESI) calcd for C₂₀H₁₈N₆O₅ (M + H)⁺: 413.1411, found: 413.1408.



2-amino-6-nitro-5,7-di-*p*-tolyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4(3*H*)-one (4f)

Pale yellow powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.91 (br, s, 1H, NH), 7.08-7.19 (m, 6H, ArH), 7.01 (d, J = 7.6 Hz, 2H, ArH), 5.35 (s, 1H, NH), 5.13 (br, s, 2H, NH₂), 4.83 (s, 1H, CH), 4.50 (d, J = 2.0 Hz, 1H, CH), 4.46 (s, 1H, CH), 2.36 (s, 3H, CH₃), 2.29 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 163.0, 159.9, 154.2, 139.2, 138.3, 137.8, 132.5, 129.9, 129.8, 128.0, 126.3, 88.9, 83.7, 52.7, 40.8, 21.1; IR (KBr, v, cm⁻¹): 3637, 3348, 1658, 1606, 1546, 1474, 1325, 1215, 1029, 850, 812, 668, 620; HRMS (ESI) calcd for C₂₁H₂₁N₅O₃ (M + H)⁺: 392.1717, found: 392.1721.



2-amino-5-(4-methoxyphenyl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4g)

Purple powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO-*d*₆, TMS): δ 10.09 (br, s, 1H, NH), 7.18-7.14 (m, 3H, ArH+NH), 7.10 (d, *J* = 8.0 Hz, 2H, ArH), 7.02(d, *J* = 8.0 Hz, 2H, ArH), 6.90 (d, *J* = 8.4 Hz, 2H, ArH), 6.19 (br, s, 2H, NH₂), 4.86 (s, 1H, CH), 4.47 (d, *J* = 3.2 Hz, 1H, CH), 4.32 (d, *J* = 2.0 Hz, 1H, CH), 3.73 (s, 3H, OMe), 2.25 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃+ DMSO-*d*₆, TMS): δ 163.0, 160.0, 154.1, 141.4, 139.2, 134.1, 132.5, 129.8, 129.3, 128.1, 128.0, 126.3, 88.8, 83.6, 55.6, 52.7, 21.1; IR (KBr, v, cm⁻¹): 3641, 3419, 3222, 2927, 1680, 1609, 1544, 1474, 1372, 1330, 1251, 1175, 1030, 843, 776; HRMS (ESI) calcd for C₂₁H₂₁N₅O₄ (M + H)⁺: 408.1666, found: 408.1665.



2-amino-5-(2-chlorophenyl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4h)

Light blue powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.69 (br, s, 1H, NH), 7.46-7.48 (m, 1H, ArH), 7.28-7.33 (m, 2H, ArH), 7.17-7.19 (m, 1H, ArH), 7.11 (d, J = 8.0 Hz, 2H, ArH), 7.02 (d, J = 8.0 Hz, 2H, ArH), 5.42 (s, 1H, NH), 5.38 (br, s, 2H, NH₂), 4.82-4.85 (m, 2H, CH), 4.46 (d, J = 3.2 Hz, 1H, CH), 2.29 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 163.0, 160.0, 154.2, 141.4, 139.2, 134.1, 132.5, 129.8, 129.3, 129.2, 128.1, 128.0, 126.3, 88.8, 83.6, 52.7, 41.2, 21.1; IR (KBr, v, cm⁻¹): 3499, 3393, 2901, 1642, 1595, 1545, 1322, 1286, 1215, 1030, 848, 700, 620; HRMS (ESI) calcd for C₂₀H₁₈ClN₅O₃ (M + H)⁺: 412.1171, found: 412.1170.



2-amino-5-(2,4-dichlorophenyl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4i)

Blue powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.80 (br, s, 1H, NH), 7.49 (d, J = 2.0 Hz, 1H, ArH), 7.28 (d, J = 1.6 Hz, 1H, ArH), 7.12-7.15 (m, 3H, ArH), 7.04 (d, J = 8.4 Hz, 2H, ArH), 5.45 (br, s, 2H, NH₂), 5.41 (s, 1H, NH), 4.80 (d, J = 2.8 Hz, 1H, CH), 4.77 (s, 1H, CH), 4.44 (d, J = 2.8 Hz, 1H, CH), 2.30 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 162.7, 160.4, 154.3, 139.5, 136.7, 134.7, 133.9, 131.9, 131.1, 129.9, 128.0, 126.3, 85.9, 82.7, 53.1, 38.2, 21.1; IR (KBr, v, cm⁻¹): 3496, 3390, 2901, 1642, 1595, 1545, 1475, 1323, 1286, 1030, 770, 700; HRMS (ESI) calcd for C₂₀H₁₇Cl₂N₅O₃ (M + H)⁺: 446.0781, found: 446.0781.



2-amino-5-(naphthalen-1-yl)-6-nitro-7-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4j)

Blue powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.62 (br, s, 1H, NH), 8.16 (d, *J* = 8.0 Hz, 1H, ArH), 7.96 (d, *J* = 7.6 Hz, 1H, ArH), 7.84 (d, *J* = 8.4 Hz, 1H, ArH), 7.55-7.61 (m, 2H, ArH), 7.43 (t, *J* = 7.2 Hz, 1H, ArH), 7.27 (s, 1H, ArH), 7.02 (d, *J* = 8.4 Hz, 2H, ArH), 6.93 (d, *J* = 8.0 Hz, 2H, ArH), 5.31 (s, 1H, NH), 5.23 (s, 1H, CH), 4.94 (s, 1H, CH), 4.50 (br, s, 3H, NH₂ + CH), 2.24 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 162.7, 160.1, 154.0, 139.2, 136.2, 134.1, 132.2, 130.1, 129.7, 129.0, 127.6, 126.9, 126.4, 125.7, 121.8, 86.7, 83.4, 53.1, 37.7, 21.1; IR (KBr, v, cm⁻¹): 3388, 2925, 1639, 1550, 1475, 1328, 1105, 1047, 770, 620; HRMS (ESI) calcd for C₂₄H₂₁N₅O₃ (M + H)⁺: 428.1717, found: 428.1731.



2-amino-6-nitro-5,7-diphenyl-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4(3*H*)-one (4k)

Blue powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.13 (br, s, 1H, NH), 7.35-7.38 (m, 2H, ArH), 7.26-7.32 (m, 6H, ArH), 7.24 (s, 1H, NH), 7.15-7.17 (m, 2H, ArH), 6.24 (br, s, 2H, NH₂), 4.97 (t, J = 2.4 Hz, 1H, CH), 4.54 (d, J = 3.6 Hz, 1H, CH), 4.41 (s, d, J = 2.0 Hz, 1H, CH); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 162.7, 161.8, 160.0, 154.4, 154.0, 142.9, 141.8, 137.4, 129.0, 128.8, 128.7, 128.6, 128.2, 127.4, 126.8, 89.3, 83.0, 53.0; IR (KBr, v, cm⁻¹): 3385, 2920, 1639, 1550, 1474, 1364, 1328, 1104, 845, 770; HRMS (ESI) calcd for C₁₉H₁₇N₅O₃ (M + H)⁺: 364.1404, found: 364.1410.



2-amino-7-(4-bromophenyl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4l)

Light blue powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.13 (br, s, 1H, NH), 7.51 (d, J = 8.4 Hz, 2H, ArH), 7.34-7.38 (m, 2H, ArH), 7.27-7.29 (m, 4H, ArH + NH), 7.13 (d, J = 8.4 Hz, 2H, ArH), 6.23 (br, s, 2H, NH₂), 5.00 (s, 1H, CH), 4.54 (d, J = 3.2 Hz, 1H, CH), 4.42 (d, J = 2.0 Hz, 1H, CH); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.2, 159.9, 154.4, 142.8, 136.9, 131.6, 129.6, 129.0, 128.6, 127.4, 121.7, 89.0, 83.1, 52.4; IR (KBr, v, cm⁻¹): 3421, 2920, 1648, 1609, 1546, 1470, 1371, 1328, 1214, 1011, 845, 676; HRMS (ESI) calcd for C₁₉H₁₆BrN₅O₃ (M + H)⁺: 442.0509, found: 442.0500.



2-amino-6-nitro-5-phenyl-7-(4-(trifluoromethyl)phenyl)-5,6,7,8-

tetrahydropyrido[2,3-d]pyrimidin-4(3H)-one (4m)

Light blue powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 11.06 (br, s, 1H, NH), 7.58 (d, *J* = 8.0 Hz, 2H, ArH), 7.35-7.41 (m, 2H, ArH), 7.27-7.32 (m, 5H, ArH), 5.56 (s, 1H, NH), 5.24 (br, s, 2H, NH₂), 4.90 (s, 1H, CH), 4.64 (d, *J* = 2.4 Hz, 1H, CH), 4.57 (s, 1H, CH); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 163.2, 159.9, 154.2, 141.0, 139.5, 129.4, 129.2, 128.1 (*J*_{CF}¹ = 11.0 Hz), 127.0, 126.1, 88.5, 83.9, 52.6; IR (KBr, v, cm⁻¹): 3498, 3393, 2900, 1641, 1594, 1544, 1474, 1384, 1322, 1285, 1029, 847, 700, 620; HRMS (ESI) calcd for C₂₀H₁₆F₃N₅O₃ (M + H)⁺: 432.1278, found: 432.1283.



2-amino-7-(2-bromophenyl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4n)

Light blue powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.20 (br, s, 1H, NH), 7.56 (d, J = 7.6 Hz, 1H, ArH), 7.26-7.40 (m, 8H, ArH), 7.15 (s, 1H, NH), 6.25 (br, s, 2H, NH₂), 5.02 (s, 1H, CH), 4.83 (s, 1H, CH), 4.53 (s, 1H, CH); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.9, 160.3, 154.4, 142.6, 135.8, 133.1, 130.7, 129.5, 128.9, 128.6, 128.3, 127.5, 122.0, 86.1, 83.8, 52.0; IR (KBr, v, cm⁻¹): 3421, 2920, 1649, 1608, 1544, 1372, 1329, 1285, 1074, 1012, 847, 677; HRMS (ESI) calcd for C₁₉H₁₆BrN₅O₃ (M + H)⁺: 442.0509, found: 442.0511.



2-amino-7-(2,4-dichlorophenyl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (40)

Light blue powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.24 (br, s, 1H, NH), 7.57 (s, 1H, ArH), 7.23-7.43 (m, 8H, ArH + NH), 6.26 (br, s, 2H, NH₂), 5.02 (s, 1H, CH), 4.86 (s, 1H, CH), 4.57 (s, 1H, CH); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 162.0, 160.2, 154.4, 142.5, 134.0, 133.7, 132.5, 130.6, 129.1, 128.9, 128.6, 127.9, 127.5,

85.9, 83.9, 49.4; IR (KBr, v, cm⁻¹): 3419, 2921, 1647, 1605, 1544, 1383, 1329, 1215, 1011, 847, 618; HRMS (ESI) calcd for $C_{19}H_{15}Cl_2N_5O_3$ (M + H)⁺: 432.0625, found: 432.0629.



2-amino-7-(2,6-dichlorophenyl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4p)

Light blue powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.14 (br, s, 1H, NH), 7.26-7.39 (m, 8H, ArH), 7.10 (s, 1H, NH), 6.24 (br, s, 2H, NH₂), 5.21 (s, 1H, CH), 4.79 (s, 1H, CH), 4.59 (s, 1H, CH); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 160.9, 158.9, 154.4, 142.9, 131.0, 130.8, 128.8, 128.7, 127.4, 84.5, 83.5, 51.7; IR (KBr, v, cm⁻¹): 3644, 3421, 2921, 1649, 1609, 1547, 1472, 1329, 1216, 873, 677; HRMS (ESI) calcd for C₁₉H₁₅Cl₂N₅O₃ (M + H)⁺: 432.0625, found: 432.0624.



2-amino-7-(4-isopropylphenyl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4q)

White powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.78 (br, s, 1H, NH), 7.35-7.42 (m, 3H, ArH), 7.34 (s, 2H, ArH), 7.17 (d, J = 8.0 Hz, 2H, ArH), 7.06 (d, J = 8.0 Hz, 2H, ArH), 5.25 (s, 1H, NH), 5.02 (br, s, 2H, NH₂), 4.89 (s, 1H, CH), 4.51-4.53 (m, 2H, CH), 2.83-2.92 (m, 1H, CH), 1.21 (s, 3H, CH₃), 1.19 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.8, 159.9, 154.4, 148.8, 143.0, 134.7, 129.0, 128.6, 127.4, 127.2, 126.8, 89.3, 82.9, 52.8, 33.5, 24.2; IR (KBr, v, cm⁻¹): 3401, 1644, 1598, 1475, 1388, 1331, 1284, 1215, 1037, 852, 775; HRMS (ESI) calcd for C₂₂H₂₃N₅O₃ (M + H)⁺: 406.1874, found: 406.1878.



2-amino-7-(4-methoxyphenyl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4r)

Grey powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.09 (br, s, 1H, NH), 7.32-7.35 (m, 2H, ArH), 7.24-7.26 (m, 3H, ArH), 7.14 (s, 1H, NH) 7.05 (d, J = 8.4 Hz, 2H, ArH), 6.84 (d, J = 8.8 Hz, 2H, ArH), 6.19 (br, s, 2H, NH₂), 4.88 (t, J = 2.6 Hz, 1H, CH), 4.48 (d, J = 3.6 Hz, 1H, CH), 4.36 (d, J = 2.0 Hz, 1H, CH), 3.70 (s, 3H, OMe); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.8, 160.0, 159.6, 154.4, 143.1, 129.1, 129.0, 128.6, 128.4, 127.4, 114.2, 89.5, 83.0, 55.5, 52.5; IR (KBr, v, cm⁻¹): 3640, 3419, 3223, 2926, 1608, 1543, 1373, 1250, 1174, 1030, 842, 774, 621; HRMS (ESI) calcd for C₂₀H₁₉N₅O₄ (M + H)⁺: 394.1510, found: 394.1522.



2-amino-7-(naphthalen-1-yl)-6-nitro-5-phenyl-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4s)

Grey powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.22 (br, s, 1H, NH), 7.87-7.95 (m, 2H, ArH), 7.38-7.49 (m, 7H, ArH), 7.20 (t, J = 7.6 Hz, 1H, ArH), 7.11 (s, 1H, NH), 6.73 (d, J = 8.4 Hz, 1H, ArH), 6.24 (br, s, 2H, NH₂), 5.35 (s, 1H, CH), 5.02 (s, 1H, CH), 4.56 (s, 1H, CH) ; ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 162.1, 160.9, 154.3, 143.2, 133.6, 132.1, 129.8, 129.7, 129.1, 128.8, 128.4, 127.7, 127.1, 126.2, 125.8, 125.1, 120.3, 87.7, 84.1, 48.6; IR (KBr, v, cm⁻¹): 3400, 1645, 1599, 1542, 1399, 1332, 1284, 852, 775; HRMS (ESI) calcd for C₂₃H₁₉N₅O₃ (M + H)⁺: 414.1561, found: 414.1557.



2-amino-7-(4-chlorophenyl)-6-nitro-5-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4t)

White powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.85 (br, s, 1H, NH), 7.24-7.39 (m, 4H, ArH), 7.09 (d, J = 8.0 Hz, 2H, ArH), 7.00 (d, J = 8.0 Hz, 2H, ArH), 5.34 (s, 1H, NH), 5.11 (br, s, 2H, NH₂), 4.85 (s, 1H, CH), 4.50 (s, 2H, CH), 2.29 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 163.0, 160.0, 154.1, 141.4, 139.2, 134.1, 132.5, 129.8, 129.3, 129.2, 128.1, 128.0, 126.3, 88.8, 83.6, 52.7, 41.2, 21.1; IR (KBr, v, cm⁻¹): 3645, 3418, 2920, 1648, 1608, 1546, 1470, 1371, 1328, 1286, 1011, 846; HRMS (ESI) calcd for C₂₀H₁₈ClN₅O₃ (M + H)⁺: 412.1171, found: 412.1179.



2-amino-7-(4-isopropylphenyl)-6-nitro-5-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4u)

White powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.08 (br, s, 1H, NH), 7.16-7.19 (m, 6H, ArH), 7.11 (s, 1H, NH), 7.06 (d, J = 8.0 Hz, 2H, ArH), 6.21 (br, s, 2H, NH₂), 4.91 (s, 1H, CH), 4.49 (d, J = 2.8 Hz, 1H, CH), 4.36 (s, 1H, CH), 2.82-2.89 (m, 1H, CH), 2.30 (s, 3H, CH₃), 1.16 (d, J = 6.8 Hz, 6H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.8, 159.9, 154.4, 148.8, 140.0, 136.5, 134.7, 129.6, 128.4, 127.2, 126.8, 89.3, 83.0, 52.7, 33.5, 24.2, 21.1; IR (KBr, v, cm⁻¹): 3400, 2961, 1643, 1598, 1541, 1476, 1388, 1329, 1215, 1035, 851, 776; HRMS (ESI) calcd for C₂₃H₂₅N₅O₃ (M + H)⁺: 420.2030, found: 420.2026.



2-amino-7-(4-methoxyphenyl)-6-nitro-5-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4v)

White powder; Mp >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.08 (br, s, 1H, NH), 7.07-7.15 (m, 7H, ArH + NH), 6.86 (s, 2H, ArH), 6.20 (br, s, 2H, NH₂), 4.87 (s, 1H, CH), 4.49 (s, 1H, CH), 4.34 (s, 1H, CH), 3.71 (s, 3H, OMe), 2.29 (s, 3H, CH₃); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 161.8, 159.9, 159.6, 154.3, 140.0, 136.5, 129.6, 129.1, 128.4, 114.2, 89.5, 83.1, 55.5, 52.4, 21.1; IR (KBr, v, cm⁻¹): 3640, 3420, 2926, 1703, 1608, 1544, 1473, 1373, 1288, 1251, 1031, 843, 774, 621; HRMS (ESI) calcd for C₂₁H₂₁N₅O₄ (M + H)⁺: 408.1666, found: 408.1671.



2-amino-6-nitro-5-phenyl-7-(thiophen-2-yl)-5,6,7,8-tetrahydropyrido[2,3*d*]pyrimidin-4(3*H*)-one (4w)

Brown powder; Mp >300 °C; ¹H NMR (400 MHz, CDCl₃ + DMSO-*d*₆, TMS): δ 10.49 (br, s, 1H, NH), 7.42 (s, 1H, ArH), 7.13 (s, 4H, ArH), 6.33 (d, *J* = 2.0 Hz, 1H, ArH), 6.14 (s, 1H, ArH), 5.97 (s, 1H, NH), 5.87 (br, s, 2H, NH₂), 5.08 (s, 1H, CH), 4.61 (d, *J* = 10.4 Hz, 2H, CH), 2.32 (s, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃ + DMSO-*d*₆, TMS): δ 164.0, 159.1, 158.3, 147.1, 143.4, 137.8, 134.5, 134.3, 131.3, 115.4, 113.5, 89.8, 86.8, 58.3, 39.9, 25.9; IR (KBr, v, cm⁻¹): 3636, 3349, 2917, 1658, 1606, 1546, 1474, 1326, 1287, 1215, 1028, 851, 812, 668; HRMS (ESI) calcd for C₁₈H₁₇N₅O₃S (M + H)⁺: 384.1125, found: 384.1131.



2-amino-7-isobutyl-6-nitro-5-(*p*-tolyl)-5,6,7,8-tetrahydropyrido[2,3-*d*]pyrimidin-4(3*H*)-one (4x)

Sheet solid; Mp 214-216 °C; ¹H NMR (400 MHz, CDCl₃, TMS): δ 10.86 (br, s, 1H, NH), 7.07-7.13 (m, 4H, ArH), 5.10 (br, s, 2H, NH₂), 4.91 (s, 1H, NH), 4.66 (s, 1H, CH), 4.45 (s, 1H, CH), 3.45 (t, *J* = 6.0 Hz, 1H, CH), 2.31 (s, 3H, CH₃), 1.65-1.72 (m, 1H, CH), 1.38 (t, *J* = 6.8 Hz, 1H, CH₂), 0.82 (d, *J* = 6.4 Hz, 3H, CH₃), 0.75 (d, *J* = 6.4 Hz, 3H, CH₃); ¹³C NMR (100 MHz, CDCl₃, TMS): δ 163.0, 159.8, 154.2, 138.4, 137.5, 129.8, 127.9, 86.5, 84.1, 46.4, 40.9, 39.8, 29.3, 24.4, 22.5, 22.0, 21.0; IR (KBr, v, cm⁻¹): 3395, 2958, 1645, 1544, 1474, 1331, 1216, 1173, 813, 618; HRMS (ESI) calcd for C₁₈H₂₃N₅O₃ (M + H)⁺: 358.1874, found: 358.1889.



2,6-diamino-5-(1-(4-methoxyphenyl)-2-nitroethyl)pyrimidin-4(3H)-one

(intermediate C)

White solid; mp: >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 9.86 (br, s, 1H, NH), 7.42 (d, J = 8.0 Hz, 2H, ArH), 6.79 (d, J = 8.0 Hz, 2H, ArH), 6.10 (br, s, 4H, NH₂), 5.38-5.43 (m, 1H, CH₂), 5.21-5.26 (m, 1H, CH₂), 4.47 (t, J = 7.6 Hz, 1H, CH), 3.69 (s, 3H, OMe); ¹³C NMR (100 MHz, DMSO- d_6 , TMS): δ 162.6, 158.3, 154.0, 133.8, 129.3, 113.3, 86.8, 78.5, 55.4.



6-amino-5-(2-nitro-1-(p-tolyl)ethyl)pyrimidine-2,4(1H,3H)-dione (6a)

White solid; mp: >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 10.28 (s, 1H), 10.00 (br, s, 1H, NH), 7.29 (d, J = 8.0 Hz, 2H, ArH), 7.04 (d, J = 8.0 Hz, 2H, ArH), 6.36 (br, s,

2H, NH₂), 5.33-5.39 (m, 1H, CH₂), 5.21-5.26 (m, 1H, CH₂), 4.51 (t, *J* = 8.0 Hz, 1H, CH), 2.22 (s, 3H, CH₃).



6-amino-5-(2-nitro-1-(*p*-tolyl)ethyl)-2-thioxo-2,3-dihydropyrimidin-4(1*H*)-one (6b) Yellow solid; mp: >300 °C; ¹H NMR (400 MHz, DMSO- d_6 , TMS): δ 11.70 (br, s, 2H, NH), 7.28 (d, J = 8.0 Hz, 2H, ArH), 7.05 (d, J = 8.0 Hz, 2H, ArH), 6.59 (br, s, 2H, NH₂), 5.35-5.41 (m, 1H, CH₂), 5.23-5.28 (m, 1H, CH₂), 4.55 (t, J = 7.6 Hz, 1H, CH), 2.22 (s, 3H, CH₃).

References:

1. X. Z. Liang, M. F. Zeng, C. Z. Qi, Carbon, 2010, 48, 1844-1848.

¹H and ¹³C NMR Spectra







S18









S22





S24

































